Physician profile
Son T DO
NPI 1285668822
$5,413.60
in general payments reported to CMS, 2019-2025
28 companies · $1,052 in 2025
The $1,052 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.13 · 2020: $388 · 2021: $205 · 2022: $238 · 2023: $1,747 · 2024: $1,684 · 2025: $1,052.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,702 · Travel and Lodging: $765 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,701.94 |
| Travel and Lodging | $765.04 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,028.79 | 2019-2025 | Skyrizi, Rinvoq |
| Boston Scientific Corporation | $954.98 | 2023 | Exalt Model D |
| Takeda Pharmaceuticals U.S.A., INC. | $676.98 | 2020-2025 | Entyvio |
| Janssen Biotech, INC. | $288.65 | 2023-2025 | Stelara, Tremfya |
| Ferring Pharmaceuticals INC. | $258.56 | 2019-2023 | Rebyota |
| Intercept Pharmaceuticals, INC. | $228.88 | 2020-2025 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $206.90 | 2024 | Iqirvo, Bylvay |
| Madrigal Pharmaceuticals | $205.33 | 2025 | Rezdiffra |
| Celgene Corporation | $187.51 | 2022-2024 | Zeposia |
| Lilly USA, LLC | $179.36 | 2024-2025 | Omvoh |
| Aimmune Therapeutics, INC. | $149.94 | 2024-2025 | Vowst, Zenpep |
| Ambu INC. | $143.35 | 2021-2022 | |
| Allergan, INC. | $135.50 | 2019-2021 | |
| Sirtex Medical INC | $101.37 | 2025 | Sir-Spheres Microspheres |
| Cook Medical LLC | $93.18 | 2025 | Hemospray |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Capsovision, INC. | $80.78 | 2024-2025 | Capsocam Plus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.22 | 2020-2025 | Xifaxan |
| Genzyme Corporation | $71.47 | 2024 | |
| Nestle Healthcare Nutrition INC. | $66.47 | 2022-2023 | |
| Merz North America, INC. | $61.92 | 2024 | |
| Gilead Sciences, INC. | $44.72 | 2021-2023 | |
| Celltrion USA INC. | $37.31 | 2024 | Zymfentra |
| Medtronic, INC. | $35.07 | 2021 | |
| Mallinckrodt Hospital Products INC. | $29.98 | 2024 | Terlivaz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.64 | 2024 | Cyltezo |
| Merck Sharp & Dohme LLC | $18.38 | 2020 | |
| Pfizer INC. | $17.12 | 2019 | |
| Ironwood Pharmaceuticals, INC | $13.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Son DO listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.